34133-59-0

Upstream product

• 99-77-4 ethyl 4-nitrobenzoate 
• 151-50-8 potassium cyanide 
• 14348-41-5 3-bromo-4-hydroxy-benzoic acid 
• 1309921-08-1 ethyl 3-cyano-4-benzyloxybenzoate 
• 1042333-73-2 benzyl 4-(benzyloxy)-3-cyanobenzoate 
• 628711-07-9 benzyl 4-(benzyloxy)-3-bromobenzoate 
• 556836-18-1 4-benzyloxy-3-cyanobenzoyl chloride 
• 946007-61-0 4-(benzyloxy)-3-cyanobenzoic acid 
• 15126-07-5 4-hydroxy-3-iodo-benzoic acid ethyl ester 
• 497-19-8 sodium carbonate 

Downstream Products

• 939051-02-2 ethyl 3-cyano-4-trifluoromethanesulfonyloxybenzoate 
• 1309921-12-7 ethyl 3-cyano-4-(1-naphthyl)benzoate 
• 1042333-64-1 2-cyano-3'-fluorobiphenyl-4-carboxylic acid 
• 1309921-13-8 C₁₄H₈FNO₂ 
• 1309921-14-9 C₁₈H₁₁NO₂ 
• 1309921-03-6 3-cyano-4-phenyl-N-(1-[2-chlorophenyl]-3-phenyl-1H-pyrazol-5-yl)benzamide 
• 1309921-04-7 3-cyano-4-(3-fluorophenyl)-N-(1-[2-chlorophenyl]-3-phenyl-1H-pyrazol-5-yl)benzamide 
• 1309921-05-8 3-cyano-4-(4-fluorophenyl)-N-(1-[2-chlorophenyl]-3-phenyl-1H-pyrazol-5-yl)benzamide 
• 1309921-06-9 3-cyano-4-(1-naphthyl)-N-(1-[2-chlorophenyl]-3-phenyl-1H-pyrazol-5-yl)benzamide 
• 1309921-25-2 C₁₈H₁₀ClNO 
• 528607-70-7 C₂₀H₁₉ClN₂O₃S 
• 528607-66-1 methyl 2-chloro-3-(3-cyano-4-isobutyloxybenzoylamino)benzoate 
• 528607-81-0 3-Cyano-4-isobutyloxy-N-(3-methoxyphenyl)thiobenzamide 
• 528607-79-6 3-Cyano-4-isobutyloxy-N-(3-methoxyphenyl)benzamide 

Relevant academic research and scientific papers

Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5

Based on SAR in the alkyne class of mGlu5 receptor negative allosteric modulators and a set of amide-based positive allosteric modulators, optimized substitution of the aryl bring was used to create substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides.

Synthesis and evaluation of 1,2,4-methyltriazines as mGluR5 antagonists

In previous studies we showed that 3-(substituted phenylethynyl)-5- methyl[1,2,4]triazine analogues of MPEP were potent antagonists of glutamate-mediated mobilization of internal calcium in an mGluR5 in vitro efficacy assay. In the present study we report

AMPA RECEPTOR POTENTIATORS

The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

XANTHINE OXIDASE INHIBITORS

The invention relates to compounds of the following formula (I) or their salts: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R2 is halogen, nitro, cyano, carboxyl, or the like; R3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR11, oxygen, or sulfur, in which R11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent; and each of Y and Z is CR12 or nitrogen, in which R12 has the same meaning as R3 above, and a xanthine oxidase inhibitor containing the compound as an active ingredient.

Aromatic Nitro-group Displacement Reactions. Part 3. Minor Products of the o-Cyanophenol Synthesis

In dipolar aprotic solvents, the action of cyanide ions on a moderately activated aromatic or heteroaromatic nitro-compound yields, in addition to the o-cyanophenol, a range of products generated through nitro-group reduction.

Preparation of cyanophenols

A process for the preparation of a cyanophenol of formula (I) SPC1 wherein Z is a substituent in the 4- or 6-position with respect to the hydroxy group, characterized in that cyanide ions are reacted in a dipolar aprotic solvent with a nitrobenzene of formula (II) SPC2 wherein Z has the same value as in formula (I) and is a group, other than a nitro group, known to withdraw electrons in substitution reactions and which does not contain a proton capable of ionizing under the defined reaction conditions if such ionization would inhibit the electron-withdrawing effect of the group Z. In formula (I) and (II) the benzene ring is optionally substituted by one or more non electron-withdrawing groups, or by one or more electron-withdrawing groups provided that such electron-withdrawing groups are in positions other than the 4- and 6-positions with respect to the hydroxy group. The compounds of formula (I) are of value in being readily hydrolysed to the corresponding salicylic acids of formula (III) SPC3 certain of which have been described in the literature as possessing a variety of pharmacological properties.